NCT00244998已完成2 期
Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Prostate-specific antigen (PSA) objective response rate (complete response [CR] or partial response [PR])
研究概览
简要总结
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with advanced prostate cancer.
详细描述
OBJECTIVES:
Primary
- Determine if the prostate-specific antigen objective response (complete and partial response) rate is > 0.2 in patients with androgen-independent advanced prostate cancer treated with fulvestrant.
Secondary
- Determine the toxicity of this drug in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Prostate-specific antigen (PSA) objective response rate (complete response [CR] or partial response [PR])
时间窗: Monthly
次要结局
- Toxicity(Every Month)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Fulvestrant in Treating Patients With Recurrent Prostate CancerProstate CancerNCT00217464Roswell Park Cancer Institute17
终止
2 期
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast CancerBreast CancerNCT00138125Translational Oncology Research International2
已完成
2 期
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial CancerOvarian CancerNCT00617188Masonic Cancer Center, University of Minnesota26
已完成
2 期
ICI 182780 in Treating Women With Metastatic Breast CancerBreast CancerNCT00012025Alliance for Clinical Trials in Oncology80
已完成
2 期
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerBreast CancerNCT00423917Alliance for Clinical Trials in Oncology36